Preneoplastic and precancerous lesions in rodents: Morphologic and molecular characteristics

Journal of Toxicologic Pathology

Volumn 15, Issue 2, 2002, Pages 123-128

  Ward, Jerrold M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Molecular lesions; Pathology of cancer; Precancerous; Preneoplastic

Indexed keywords

EID: 1842563200     PISSN: 09149198     EISSN: 09149198     Source Type: Journal    
DOI: 10.1293/tox.15.123     Document Type: Article

References (62)

1. Henson DE and Albores-Saavedra J. Pathology of Incipient Neoplasia. 3rd ed., New York: Oxford University Press, 839, 2001.
2. Mohr U. International Classification of Rodent Tumors. The Mouse. Berlin: Springer, 474, 2001.
3. Maronpot RR. Pathology of The Mouse. Vienna, IL: Cache River Press, 699, 1999.
4. Ward JM, Mahler JF, Maronpot RR, and Sundberg JP. Pathology of Genetically Engineered Mice. Ames, Iowa: Iowa State University Press, 394, 2000.
5. Mendelsohn J, Howley PM, Israel MA, and Eiotta LA. The Molecular Basis of Cancer, 2nd ed., Philadelphia: WB Saunders Co., 289-312, 2001.
6. Jang JJ, Weghorst CM, Henneman JR, Devor DE, and Ward JM. Progressive atypia in spontaneous and Nnitrosodiethylamine induced hepatocellular adenomas of C3H/HeNCr mice evaluated by image analysis. Carcinogenesis 1992; 13: 1541-1547.
7. Fearon ER and Gruber SB. Molecular abnormalities in colon and rectal cancer. In: The Molecular Basis of Cancer, 2nd ed., J Mendelsohn, PM Howley, MA Israel, and LA Liotta (eds), Philadelphia: WB Saunders Co., 289-312, 2001.
8. Sills RC, Borman GA, Neal JE, Hong HL, and Devereux TR. Mutations in ras genes in experimental tumours of rodents. In: The Use of Short- and Medium-term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation, DB McGregor, JM Rice, and S Venitt (eds), Lyon: IARC Sci Publ No. 146, 55-86, 1999.
9. Perantoni AO and Rice JM. Mutation patterns in non-ras oncogenes and tumour suppressor genes in experimentally induced tumours. IARC Sci Publ 1999; 146: 87-122.
10. Leone-Kabler S, Wessner LL, McEntee MF, D'Agostino, Jr RB, and Miller MS. Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors. Carcinogenesis 1997; 18: 1163-1168.
11. Miyamoto S, Sukumar S, Guzman RC, Osborn RC, and Nandi S. Transforming c-Ki-ras mutation is a preneoplasticevent in mouse mammary carcinogenesis induced in vitro by N-methyl-N-nitrosourea. Mol Cell Biol 1990; 10: 1593-1599.
12. Horio Y, Chen P, Roth JA, Malkinson AM, and Schrump DS. K-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog 1996; 17: 217-223.
13. Brodie SG, Xu X, Qiao W, Li WM, Cao L, and Deng CX. Multiple genetic changes are associated with mammary tumorigenesis in Brcal conditional knockout mice. Oncogene 2001; 20: 7514-7523.
14. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, and Couldrey C. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000; 19: 1020-1027.
15. Maronpot RR, Fox T, Malarkey DE, and Goldsworthy TL. Mutations in the ras proto-oncogene: clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 1995; 101: 125-156.
16. Boivin-Angele S, Lefrancois L, Froment O, Spiethoff A, Bogdanffy MS, Wegener K, Wesch H, Barbin A, Bancel B, Trepo C, Bartsch H, Swenberg J, and Marion MJ. Ras gene mutations in vinyl chloride-induced liver tumours are carcinogen-specific but vary with cell type and specifics. Int J Cancer 2000; 85: 223-227.
17. Manam S, Storer RD, Prahalada S, Leander KR, Kraynak AR, Ledwith BJ, van Zwieten MJ, Bradley MO, and Nichols WW. Activation of the Ha-, Ki-, and N-ras genes in chemically induced liver tumors from CD-1 mice. Cancer Res 1992; 52: 3347-3352.
18. Richardson KK, Helvering LM, Copple DM, Rexroat MA, Linville DW, Engelhardt JA, Todd GC, and Richardson FC. Genetic alterations in the 61st codon of the H-ras oncogene isolated from archival sections of hepatic hyperplasias, adenomas and carcinomas in control groups of B6C3F1 mouse bioassay studies conducted from 1979 to 1986. Carcinogenesis 1992; 13: 935-941.
19. Hayashi S-M, Hong H-HL, Toyoda K, Ton T-VT, Devereux TR, Maronpot RR, Huff J, and Sills RC. High frequency of ras mutations in forestomach and lung tumors of B6C3F1 mice exposed to 1-amino-2,4-dibromoanthraquinone for 2 years. Toxicol Pathol 2001; 29: 422-429.
20. Malkinson AM. Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res 1998; 24: 541-555
21. Miller MS, Leone-Kabler S, Rollins LA, Wessner LL, Fan M, Schaeffer DO, McEntee MF, and O'Sullivan MG. Molecular pathogenesis of transplacentally induced mouse lung tumors. Exp Lung Res 1998; 24: 557-577.
22. Duddy SK, Gorospe SM, Bleavins MR, and delaIglesia FA. Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies. Toxicol Appl Pharmacol 1999; 160: 133-140.
23. Nagao M, Ushijima T, Toyota M, Inoue R, and Sugimura T. Genetic changes induced by heterocyclic amines. Mutat Res 1997; 376: 161-167.
24. Tamano S, Ward JM, Diwan BA, Keefer LK, Weghorst CM, Calvert RJ, Henneman JR, Ramljak D, and Rice JM. Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrtes (nitroglycerin) in male F344 rats. Carcinogenesis 1996; 17: 2477-2486.
25. Watatani M, Perantoni AO, Reed CD, Enomoto T, Wenk ML, and Rice JM. Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl(acetoxymethyl)nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats. Cancer Res 1989; 49: 1103-1109.
26. Enomoto T, Ward JM, and Perantoni AO. H-ras activation and ras p21 expression in bladder tumors induced in F344/ NCr rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 1990; 11: 2233-2238.
27. Stegelmeier BL, Gillett NA, Rebar AH, and Kelly G. The molecular progression of plutonium-239-induced rat lung Carcinogenesis: Ki-ras expression and activation. Mol Carcinog 1991; 4: 43-51.
28. Buchmann A, Mahr J, Bauer-Hofmann R, and Schwartz M. Mutations at codon 61 of the Ha-ras proto-oncogene in precancerous liver lesions of the B6C3F1 mouse. Mol Carcinog 1989; 2: 121-125.
29. Bauer-Hofmann R, Klimek F, Buchmann A, Muller O, Bannasch P, and Schwarz M. Role of mutations at codon 61 of the c-Ha-ras gene during diethylnitrosamine-induced hepatocarcinogensis in C3H/He mice. Mol Carcinog 1992; 6: 60-67.
30. Tachino N, Hayashi R, Liew C, Bailery G, and Dashwood R. Evidence for ras gene mutation in 2-amino-3-methylimidazo[4,5-f]quinoline-induced colonie aberrant crypts in the rat. Mol Carcinog 1995; 12: 187-192.
31. Stopera SA, Murphy LC, and Bird RP. Evidence for a ras gene mutation in azoxymethane-induced colonie aberrant crypts in Sprague-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer. Carcinogenesis 1992; 13: 2081-2085.
32. Zhu H, Zhang X, and Chen Y. The expression of mutant (mp53) protein in rat hepatic preneoplastic lesions induced by diethylnitrosamine (DEN). Zhonghua Zhong Liu Za Zhi 1997; 19: 22-24.
33. Hegi ME, Soderkvist P, Foley JF, Schoonhoven R, Swenberg JA, Kari F, Maronpot R, Anderson MW, and Wiseman RW. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis 1993; 14: 803-810.
34. Yamamoto S, Tatematsu M, Yamamoto M, Fukami H, and Fukushima S. Clonal analysis of urethelial carcinomas in C3H/HeN↔BALB/c chimeric mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 1998; 19: 855-860.
35. Queille S, Seite S, Tison S, Medaisko C, Drougard C, Fourtanier A, Sarasin A, and Daya-Grosjean L. p53 mutations in cutaneous lesions induced in the hairless mouse by a solar ultraviolet light simulator. Mol Carcinog 1998; 22: 167-174.
36. Stenback F, Makinen M, and Jussila T. p53 expression in skin Carcinogenesis and its relationship to cell proliferation and tumour growth. Eur J Cancer 1998; 34: 1415-1424.
37. Calvisi DF, Factor VM, Loi R, and Thorgeirsson SS. Activation of β-catenin during hepatocarcinogenesis in transgenic mouse models: Relationship to phenotype and tumor grade. Cancer Res 2001; 61: 2085-2091.
38. Devereux TR, Anna CH, Foley JF, White CM, Sills RC, and Barrett JC. Mutation of β-catenin is an early event inchemically induced mouse hepatocellular carcinogenesis. Oncogene 1999; 18: 4726-4733.
39. Ogawa K, Yamada Y, Kishibe K, Ishizaki K, and Tokusashi Y. β-Catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice. Cancer Res 1999; 59: 1830-1833.
40. Takahashi M, Nakatsugi S, Sugimura T, and Wakabayashi K. Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000; 21: 1117-1120.
41. Shiina H, Igawa M, Urakami S, Shigeno K, Yoneda T, Terashima M, Deguchi M, Ribeiro-Filho L, and Dahiya R. Alterations of beta- and gamma-catenin in N-bulyl-N-(-4-hydroxybutyl) nitrosamine-induced murine bladder cancer. Cancer Res 2001; 61: 7101-7109.
42. Yamada Y, Yoshimi N, Hirose Y, Kawabata K, Matsunaga K, Shimizu M, Hara A, and Mori H. Frequent β-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000; 60: 3323-3327.
43. Yamada Y, Yoshimi N, Hirose Y, Matsunaga K, Katayama M, Sakata K, Shimizu M, Kuno T, and Mori H. Sequential analysis of morphological and biological properties of β-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001; 61: 1874-1878.
44. Koesters R, Hans MA, Benner A, Prosst R, Boehm J, Gahlen J, and Doeberitz MK. Predominant mutation of codon 41 of the β-catenin proto-oncogene in rat colon tumors induced by 1,2-dimethylhydrazine using a complete carcinogenic protocol. Carcinogenesis 2001; 22: 1885-1890.
45. Takahashi M, Fukuda K, Sugimura T, and Wakabayashi K. β-Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res 1998; 58: 42-46.
46. Andreassen A, Vikse R., Steffensen IL, Paulsen JE, and Alexander J. Intestinal tumors induced by the food carcinogen 2-amino-1 -methyl-6-phenylimidazo[4,5b]pyridine in multiple intestinal Neoplasia mice have truncation mutations as well as loss of the wild-type Apc(+) allele. Mutagenesis 2001; 16: 309-315.
47. Δ716 mouse intestinal polyps. Cancer Res 2002; 62: 506-511.
48. French J, Storer RD, and Donehower LA. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol 2001; 29: 24-29.
49. Lawler J, Miao W-M, Duquette M, Bouck N, Bronson RT, and Hynes RO. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 2001; 159: 1949-1956.
50. +/- mouse model in carcinogenicity testing. Toxicol Pathol 2001; 29: 147-154.
51. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa DC, Marx SJ, Spiegel AM, and Collins FS. A mouse model of multiple endocrine Neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 2001; 98: 1118-1123.
52. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, and Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2002; 99: 2884-2889.
53. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, and Mak TW. High incidence of breast and endometrial Neoplasia resembling human Cowden syndrome in pten +/mice. Cancer Res 2000; 60: 3605-3611.
54. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, and Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-1568.
55. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, and Ittmann M. Haploindufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001; 98: 11563-11568.
56. Haines J, Dunford R, Moody J, Eilender MJ, Cox R, and Silver A. Loss of heterozygosity in spontaneous and X-rayinduced intestinal tumors arising in F1 hybrid min mice: evidence for sequential loss of APC(+) and Dpc4 in tumor development. Genes Chromosomes Cancer 2000; 28: 387-394.
57. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, and Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999; 59: 1206-1211.
58. Kobayashi T, Minowa O, Sugitani Y, Takai S, Mitani H, Kobayashi E, Noda T, and Hino O. A germ-line Tscl mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice. Proc Natl Acad Sci USA 2001; 98: 8762-8767.
59. Davis LM, Caspary WJ, Sakallah SA, Maronpot RR, Wiseman R, Barrett JC, Elliot R, and Hozier JC. Loss of heterozygosity in spontaneous and chemically induced tumors of the B6C3F1 mouse. Carcinogenesis 1994; 15: 1637-1645.
60. Santos J, Herranz M, Fernandez M, Vaquero C, Lopez P, and Fernandez-Piqueras J. Evidence of a possible epigenetic inactivation mechanism operating on a region of mouse chromosome 19 in gamma-radiation-induced thymic lymphomas. Oncogene 2001; 20: 2186-2189.
61. Ritland SR, Rowse GJ, Chang Y, and Gendler SJ. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 1997; 57: 3520-3525.
62. Hunt JD, Mera R, Strimas A, Gillespie AT, Ruiz B, Correa P, and Fontham ETH. KRAS mutations are not predictive for progression of preneoplastic gastric lesions. Cancer Epidemiol Biomarkers Prev 2001; 10: 79-80.